The direct oral anticoagulants (DOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are licensed for stroke prevention in patients with atrial fibrillation and for prevention and treatment of venous thromboembolism [1]. As a class, the DOACs are at least as effective as vitamin ...
Fifth, OAC reversal strategies, such as the use of vitamin K, fresh frozen plasma, or intravenous factor concentrates, were not collected in the database. Idarucizumab was approved by the US Food and Drug Administration on October 19, 2015, but only 37.0% of patients taking NOACs were ...
ApixabanEdoxabanFor more than 50聽years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved ...
ApixabanbleedingdabigatranedoxabanNOACrivaroxabanIn recent years, non-vitamin K antagonist oral anticoagulants (NOACs) have become an increasingly popular choice in the treatment and prevention of venous and arterial thromboembolism, owing to the convenience of fixed dosing. Large Phase III studies and ...
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patient... Peter,Br?nnum,Nielsen,... - Bmj 被引量: 103发表: 2017年 Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the...
Dabigatran, a direct thrombin inhibitor, was also non-inferior to standard therapy for the prevention of recurrent VTE or VTE-related death when given after a parenteral anticoagulant and had a similar incidence of major bleeding. The results of a phase III study of apixaban, another direct ...
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversalDabigatranRivaroxabanTranexamic AcidApixabanRecombinant Factor VIIaFour nonvitamin K antagonist oral anticoagulants (NOACs) are approved for the prevention of stroke in patients with nonvalvular atrial fibrillation and for...
ApixabanProthrombin Complex ConcentrateDabigatran EtexilatePerioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and reversal therapies, management requires knowledge and ...
Dabigatran, rivaroxaban, and apixaban are at least as effective as warfarin in stroke risk reduction. With new mechanisms of action and no need for therapeutic drug monitoring, countless new patients are potential candidates for anticoagulation. However patient adherence, lack of a reversal agent, ...
Apixaban activity peaks 3 h after intake and has a half life of 9–14 h [32]. Bioavailability of apixaban is 66%, and apixaban is partly (25%) excreted by the kidneys. 3. Clinical Trials with Oral Anticoagulation Drugs 3.1. Vitamin K Antagonists (VKA) The promise and later importance ...